Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer

Area of Science:

• Molecular Biology
• Cancer Research
• RNA Therapeutics

Background:

• Dysregulated adenosine-to-inosine (A-to-I) RNA editing is linked to cancer development.
• Currently, no specific inhibitors exist for cancer-associated RNA editing events.

Purpose of the Study:

• To investigate the RNA secondary structure of antizyme inhibitor 1 (AZIN1), a key A-to-I editing target in cancer.
• To develop and evaluate antisense oligonucleotides (ASOs) as potential inhibitors of AZIN1 RNA editing.

Main Methods:

• Deciphered AZIN1 RNA secondary structure, identifying the editing site complementary sequence (ECS).
• Designed and tested chemically modified ASOs targeting AZIN1's editing region and ECS.
• Assessed ASO efficacy in vitro (cancer cell viability) and in vivo (xenograft tumor models).
• Optimized ASO chemistry using 2'-O-methyl (2'-O-Me) sugar and phosphorothioate (PS) backbone modifications.

Main Results:

• ECS-targeting ASOs effectively inhibited AZIN1 editing without impacting splicing or translation.
• ASO3.2, targeting the ECS, demonstrated specific inhibition of cancer cell viability in vitro.
• ASO3.2 significantly reduced tumor incidence and growth in xenograft models.

Conclusions:

• Targeting the AZIN1 ECS with chemically modified ASOs is a viable strategy for cancer therapy.
• Optimized ASO chemistry (2'-O-Me/PS) enhances editing inhibition efficacy.
• AZIN1-targeting ASO-based therapeutics show promise for treating a broad spectrum of cancer types.